Ocular Therapeutix received a Buy (speculative) rating with a 12-month price target of $7.90 following strong Phase 3 SOL-1 trial results. The positive data supports a clear regulatory path, with a New Drug Application (NDA) filing expected in Q4 and a potential product launch in 2027. Despite the promising results, the market prices in $1.26 billion peak U.S. sales, reflecting competition, lost takeover premium, and rising cash burn. Investors are advised to keep position sizes small due to a wide range of possible outcomes, from $3 to over $20 per share, depending on launch execution and delayed efficacy data.
Ocular Therapeutix and its recent developments provide context for health sector trends on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Oct 25, 2026 13:41 WIB: out of 150 priced health-sector US stocks, 44 rose and 105 fell today. Notably, Liquidia Corporation (LQDA) gained 7.46% to USD 42.65 with a typical hold time of 3 days, contrasting with Oscar Health Inc (OSCR), which dropped 6.99% to USD 30.99 and has a typical hold time of 16 days. Inovio Pharmaceuticals (INO) rose 6.94% to USD 0.90, with all Pluang order activity on the buy side and a typical hold time of 43 days.
Worldcoin (WLD) experienced a sharp decline of 4.83% within one hour, falling to $0.4434 on October 25, with a 24-hour drop of 5.54%. This price movement coincided with $1.64 million in long liquidations across major exchanges Binance, Bybit, and OKX...
Sui (SUI) token dropped 3.26% as two major rollouts approach: Hashi's phased mainnet launch and Samsung Wallet's stablecoin feature. Hashi enables Bitcoin to be used as collateral on Sui via hBTC, supporting Bitcoin-backed financial products like len...
Bitcoin's price recovered to around $80,600 on October 25 after briefly falling below $80,000 during a weekend sell-off that caused $546.88 million in liquidations across crypto markets. U.S. spot Bitcoin ETFs saw significant withdrawals totaling abo...
A 25-times-leveraged Ether (ETH) long position was fully liquidated during a brief crypto market drop, resulting in a net loss exceeding $180,000. The trader later reopened a smaller long position holding 115 ETH, valued at about $269,000, with a liq...
Avalanche (AVAX) was trading at $8.85 as of early October 25, slightly down by 1.02% over the past 24 hours. Crypto analyst Giannis Andreou identified a support range between $8.50 and $8.90, which AVAX is currently within. If this support holds, And...
